Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Insider

JAZZ

Jazz Pharmaceuticals plc

Sep 15 • 03:33PM ET

125.25

-0.91 -0.72 %

Healthcare • Biotechnology • Ireland • NASD

Peers: VRTX REGN BIIB INCY GILD BMRN NBIX EXEL UTHR SAGE

| Held by: IJH VTI VB VBR VXF CALF MDY IJJ SPMD DFAT

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-6.75	Insider Own	4.85%	Shs Outstand	60.64M	Perf Week	-3.54%
Market Cap	7.60B	Forward P/E	5.83	EPS next Y	21.49	Insider Trans	3.14%	Shs Float	57.72M	Perf Month	7.36%
Enterprise Value	11.36B	PEG	-	EPS next Q	5.96	Inst Own	102.33%	Short Float	9.90%	Perf Quarter	15.44%
Income	-404.84M	P/S	1.86	EPS this Y	-74.66%	Inst Trans	3.53%	Short Ratio	7.82	Perf Half Y	-9.21%
Sales	4.09B	P/B	2.05	EPS next Y	305.84%	ROA	-3.63%	Short Interest	5.71M	Perf YTD	1.71%
Book/sh	61.12	P/C	4.55	EPS next 5Y	4.66%	ROE	-10.84%	52W High	148.06 -15.40%	Perf Year	19.14%
Cash/sh	27.53	P/FCF	6.01	EPS past 3/5Y	- -1.00%	ROIC	-5.00%	52W Low	95.49 31.17%	Perf 3Y	-17.35%
Dividend Est.	-	EV/EBITDA	8.83	Sales past 3/5Y	9.56% 13.48%	Gross Margin	73.23%	Volatility	2.31% 2.26%	Perf 5Y	-9.41%
Dividend TTM	-	EV/Sales	2.78	EPS Y/Y TTM	-205.13%	Oper. Margin	15.03%	ATR (14)	3.03	Perf 10Y	-22.77%
Dividend Ex-Date	-	Quick Ratio	1.37	Sales Y/Y TTM	4.52%	Profit Margin	-9.91%	RSI (14)	53.85	Recom	1.20
Dividend Gr. 3/5Y	- -	Current Ratio	1.62	EPS Q/Q	-584.94%	SMA20	-0.26%	Beta	0.27	Target Price	186.44
Payout	0.00%	Debt/Eq	1.47	Sales Q/Q	2.14%	SMA50	5.66%	Rel Volume	0.55	Prev Close	126.16
Employees	2800	LT Debt/Eq	1.18	Earnings	Aug 05 AMC	SMA200	4.86%	Avg Volume	730.84K	Price	125.25
IPO	Jun 01, 2007	Option/Short	Yes / Yes	EPS/Sales Surpr.	-8.47% -0.14%	Trades		Volume	374,399	Change	-0.72%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-15-25	Initiated	Deutsche Bank	Buy	$152
Mar-07-25	Upgrade	UBS	Neutral → Buy	$145 → $179
Feb-26-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-13-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$130 → $170
Dec-12-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$140 → $175
Jun-05-24	Initiated	Goldman	Buy	$169
Jan-03-24	Initiated	Robert W. Baird	Outperform	$160
Nov-27-23	Downgrade	UBS	Buy → Neutral	$170 → $135
Sep-29-23	Initiated	Raymond James	Mkt Perform
Jun-12-23	Resumed	Wells Fargo	Equal Weight	$184 → $140
Dec-09-22	Upgrade	Goldman	Neutral → Buy	$192 → $190
Jun-14-22	Initiated	UBS	Buy	$194
Apr-06-22	Downgrade	Goldman	Buy → Neutral	$202 → $196
Nov-19-21	Resumed	Goldman	Buy	$198
Oct-07-21	Resumed	Jefferies	Buy	$172
Oct-05-21	Initiated	Citigroup	Buy	$200
Sep-23-21	Initiated	Needham	Buy	$220
May-19-21	Resumed	JP Morgan	Overweight	$183 → $206
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$186
Feb-05-21	Reiterated	H.C. Wainwright	Buy	$195 → $207

Show Previous Ratings

Sep-09-25 07:45AM	Modeyso (dordaviprone) Included in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma (PR Newswire)
Sep-02-25 01:34AM	Jazz Pharmaceuticals (JAZZ) Price Target Raised After Modeyso Commercial Strategy Update (Insider Monkey)
Aug-29-25 12:27PM	Axsome Shares Up 20% in a Month: How Should You Play the Stock? (Zacks)
05:04AM	Jazz Pharmaceuticals plc (JAZZ) Wins FDA Accelerated Approval for Modeyso Brain Cancer Therapy (Insider Monkey)
Aug-28-25 11:49PM	Jazz Pharmaceuticals (JAZZ) Sings License with Saniona for SAN2355 (Insider Monkey)
11:57PM	Loading…
Aug-22-25 11:57PM	BofA Raises PT on Jazz Pharmaceuticals (JAZZ) to $225 From $217 (Insider Monkey)
06:27AM	FDA cancels adcomm on Biohaven drug; Catalent lays off staff (BioPharma Dive)
Aug-21-25 04:15PM	Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference (PR Newswire)
09:49AM	JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug (Zacks)
Aug-20-25 04:15PM	Jazz Pharmaceuticals to Host Modeyso (dordaviprone) Investor Webcast on August 27, 2025 (PR Newswire)
07:30AM	Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355 (PR Newswire)
Aug-19-25 07:17PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research)
Aug-17-25 11:35PM	Q2 Rundown: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Other Pharmaceuticals Stocks (StockStory)
Aug-14-25 04:03AM	United States Narcolepsy Drugs Market to Reach US$ 2,233.56 Million by 2033 - 7.88% CAGR Driven by Novel Therapies and Better Diagnosis (GlobeNewswire)
Aug-13-25 04:30PM	Onco360 adds Modeyso (dordaviprone) to portfolio of Oncology and Rare Cancer therapies as a National Specialty Pharmacy Provider (GlobeNewswire)
12:16AM	Loading…
12:16AM	The 5 Most Interesting Analyst Questions From Jazz Pharmaceuticals's Q2 Earnings Call (StockStory)
Aug-12-25 11:48PM	JAZZ Q2 Deep Dive: Pipeline Milestones and Oncology Headwinds Shape Outlook (StockStory)
Aug-08-25 09:15AM	Don't Overlook Jazz (JAZZ) International Revenue Trends While Assessing the Stock (Zacks)
05:07AM	Elevidys sales weaken; Neumora gets into obesity (BioPharma Dive)
Aug-07-25 03:35PM	Why Jazz Pharmaceuticals (JAZZ) Stock Is Trading Up Today (StockStory) +5.81%
05:00AM	FDA gives accelerated approval to Jazz Pharmas diffuse midline glioma therapy (Pharmaceutical Technology)
Aug-06-25 07:08PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research) -6.42%
03:07PM	Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma (PR Newswire)
09:22AM	JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut (Zacks)
03:29AM	Jazz Pharmaceuticals PLC (JAZZ) Q2 2025 Earnings Call Highlights: Strong Neuroscience ... (GuruFocus.com)
Aug-05-25 06:30PM	Jazz (JAZZ) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
06:13PM	Jazz Pharmaceuticals (NASDAQ:JAZZ) Reports Q2 In Line With Expectations But Stock Drops (StockStory)
05:15PM	Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:13PM	Jazz: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance (PR Newswire)
11:36AM	Loading…
11:36AM	AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y (Zacks)
Aug-03-25 11:01PM	Jazz Pharmaceuticals (JAZZ) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
Jul-30-25 11:44AM	Morgan Stanley Reduces PT on Jazz Pharmaceuticals plc (JAZZ) from $166 to $165; Maintains 'Buy' Rating (Insider Monkey)
10:00AM	Sarepta Therapeutics (SRPT) to Report Q2 Results: Wall Street Expects Earnings Growth (Zacks)
Jul-29-25 10:00AM	Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q2 Earnings Expected to Decline (Zacks)
Jul-24-25 07:00PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research)
Jul-22-25 04:15PM	Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025 (PR Newswire)
09:39AM	Strength Seen in ABCELLERA BIOLG (ABCL): Can Its 15.0% Jump Turn into More Strength? (Zacks)
09:39AM	ALKS Down Despite Positive Top-Line Data From Narcolepsy Study (Zacks)
Jul-21-25 04:12PM	Why Alkermes Tumbled On Its Positive Narcolepsy Study (Investor's Business Daily)
01:29PM	Alkermes Offers The Next Proof Point For Its Narcolepsy Approach. Stock Dives. (Investor's Business Daily)
Jul-14-25 11:30AM	Jazz Pharmaceuticals (JAZZ) Highlights Growth at Goldman Sachs Healthcare Conference (Insider Monkey)
Jul-11-25 07:51AM	Jazz names new CEO; Ultragenyx, Mereo shares slide on trial update (BioPharma Dive)
Jul-10-25 08:00AM	Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity (Investor's Business Daily)
07:30AM	Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer (PR Newswire)
Jul-08-25 12:05AM	3 Reasons to Sell JAZZ and 1 Stock to Buy Instead (StockStory)
Jul-07-25 01:00AM	Nuevocor Strengthens Board with Appointment of Thierry Abribat (PR Newswire)
Jul-06-25 04:00AM	Jazz Pharmaceuticals' Ziihera Receives Conditional European Approval for Advanced Biliary Tract Cancer (Insider Monkey)
Jul-04-25 07:48AM	Here's Why Harmony Biosciences Is an Unconventional Cannabis Investment (Zacks)
Jul-02-25 05:21AM	EC approves Jazz Pharmaceuticals Ziihera for biliary tract cancer (Pharmaceutical Technology)
02:46AM	Jazz Pharmaceuticals Gets UBS Buy Rating After Strong ASCO 2025 Trial Results (Insider Monkey)
Jul-01-25 08:31AM	Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer (PR Newswire)
Jun-27-25 05:22AM	The 5 Most Interesting Analyst Questions From Jazz Pharmaceuticals's Q1 Earnings Call (StockStory)
Jun-11-25 07:59PM	Jazz Pharmaceuticals Releases Unexpected Phase 4 Results Highlighting Xywav (Insider Monkey)
Jun-10-25 07:05AM	Zepzelca (lurbinectedin) and Atezolizumab (Tecentriq) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer (PR Newswire)
Jun-09-25 06:00PM	Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025 (PR Newswire)
Jun-05-25 11:30AM	Why Is Jazz (JAZZ) Up 7.9% Since Last Earnings Report? (Zacks)
Jun-02-25 04:05PM	Jazz Pharmaceuticals Announces Zepzelca (lurbinectedin) and Atezolizumab (Tecentriq) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer (PR Newswire)
12:35PM	Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025 (PR Newswire)
May-29-25 07:30AM	Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025 (PR Newswire)
May-23-25 06:02AM	Insiders Pour Millions into These 3 Stocks Heres Why They Draw Plaudits Across the Board (TipRanks)
May-21-25 04:30PM	Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences (PR Newswire)
May-19-25 09:53AM	JAZZ Q1 Earnings Call: Revenue and Profit Miss, Product Pipeline Drives Outlook (StockStory)
May-13-25 09:16AM	Unlocking Jazz (JAZZ) International Revenues: Trends, Surprises, and Prospects (Zacks)
May-10-25 11:55AM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
May-09-25 08:51AM	Pharma Stock Roundup: NVO & JAZZ's Q1 Results, AZN's Pipeline Update (Zacks)
May-08-25 06:36PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research)
07:20AM	Cannabis Stock Tilray Brands Loses 19% in a Month: Time to Sell or Hold? (Zacks)
May-07-25 07:13PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research) -8.75%
11:55AM	JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook (Zacks)
11:00AM	Appeals court reverses-in-part, vacates-in part ruling in Avadel-Jazz fight (TipRanks)
08:33AM	Jazz Pharmaceuticals (JAZZ): Among Billionaire Ray Dalio's Bridgewater's Stock Picks with Huge Upside Potential (Insider Monkey)
03:19AM	Jazz Pharmaceuticals PLC (JAZZ) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
May-06-25 11:06PM	Jazz Pharmaceuticals plc (JAZZ) Q1 2025 Earnings Call Transcript (Seeking Alpha) -5.94%
06:30PM	Here's What Key Metrics Tell Us About Jazz (JAZZ) Q1 Earnings (Zacks)
05:20PM	Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates (Zacks)
04:05PM	Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance (PR Newswire)
09:39AM	AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y (Zacks)
May-05-25 09:40AM	Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock (Zacks)
May-02-25 07:41PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research)
May-01-25 10:01AM	Illumina (ILMN) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-30-25 04:15PM	Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference (PR Newswire)
07:18AM	Buy, Sell or Hold JAZZ Stock? Key Tips Ahead of Q1 Earnings (Zacks)
Apr-29-25 09:30PM	Franklin Convertible Securities Fund Q1 2025 Commentary (Seeking Alpha)
10:01AM	Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy? (Zacks)
08:14AM	3 Unconventional Cannabis Stocks to Watch in 2025 (Zacks)
Apr-28-25 05:33PM	Zymeworks: A Strong Buy With Newly-Approved Cancer Drug, Excellent Financials, And Expansive Pipeline (Seeking Alpha)
05:05AM	3 Reasons to Sell JAZZ and 1 Stock to Buy Instead (StockStory)
Apr-25-25 11:27AM	Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer (PR Newswire)
Apr-23-25 04:15PM	Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma (PR Newswire)
11:17AM	Buy 5 High ROE Stocks as Markets Break Tariff-Induced Losing Streak (Zacks)
Apr-22-25 04:15PM	Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025 (PR Newswire)
07:21AM	Cardiol Therapeutics Stock: Is Cannabis Potential Priced In? (Zacks)
Apr-21-25 04:05PM	Jazz Pharmaceuticals Completes Acquisition of Chimerix (PR Newswire)
09:22AM	Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria (Zacks)
07:36AM	JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play? (Zacks)
Apr-17-25 11:40AM	JAZZ vs. ARGX: Which Stock Is the Better Value Option? (Zacks)
09:40AM	Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term (Zacks)
07:49AM	Is Jazz Pharmaceuticals a Top Cannabis Investment for 2025? (Zacks)
05:06AM	Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers (StockStory)

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
COZADD BRUCE C	Director	Sep 02 '25	Sale	128.62	6,000	771,690	429,973	Sep 04 05:48 PM
Winningham Rick E	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 03:02 PM
Kennedy Patrick	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:56 PM
ENRIGHT PATRICK G	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:46 PM
RIEDEL NORBERT G	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:40 PM
Smith Mark Douglas	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:33 PM
Hamill Laura	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:26 PM
O'Keefe Kenneth W	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:20 PM
Cook Jennifer E.	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:13 PM
McSharry Heather Ann	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:06 PM
ORiordan Anne	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:00 PM
COZADD BRUCE C	Chairman & CEO	Aug 01 '25	Sale	113.21	1,000	113,210	435,973	Aug 05 04:54 PM
COZADD BRUCE C	Officer	Aug 01 '25	Proposed Sale	121.80	9,000	1,096,210		Aug 01 03:28 PM
COZADD BRUCE C	Chairman & CEO	Jul 01 '25	Sale	107.63	1,000	107,630	436,973	Jul 03 02:56 PM
COZADD BRUCE C	Officer	Jul 01 '25	Proposed Sale	107.63	1,000	107,630		Jul 01 04:15 PM
COZADD BRUCE C	Chairman & CEO	Jun 03 '25	Sale	110.00	500	55,000	437,973	Jun 04 04:50 PM
COZADD BRUCE C	Chairman & CEO	Jun 02 '25	Sale	107.90	500	53,950	438,473	Jun 04 04:50 PM
COZADD BRUCE C	Officer	Jun 02 '25	Proposed Sale	108.95	1,000	108,950		Jun 02 05:03 PM
Mulligan Seamus	Director	May 09 '25	Buy	98.26	100,000	9,826,120	100,000	May 13 06:51 PM
Mulligan Seamus	Director	May 12 '25	Buy	103.00	1,621	166,962	101,621	May 13 06:51 PM
COZADD BRUCE C	Chairman & CEO	May 01 '25	Sale	116.35	1,000	116,350	439,307	May 05 07:00 PM
COZADD BRUCE C	Chairman & CEO	May 02 '25	Sale	120.00	500	60,000	438,807	May 05 07:00 PM
COZADD BRUCE C	Officer	May 01 '25	Proposed Sale	117.57	1,500	176,350		May 01 04:09 PM
COZADD BRUCE C	Chairman & CEO	Apr 01 '25	Sale	123.75	1,500	185,625	440,307	Apr 03 05:32 PM
COZADD BRUCE C	Officer	Apr 01 '25	Proposed Sale	125.31	2,000	250,625		Apr 01 04:32 PM
Iannone Robert	EVP, Global Head of R&D & CMO	Mar 10 '25	Sale	138.41	2,403	332,605	79,621	Mar 12 02:24 PM
Carr Patricia	SVP, Chief Accounting Officer	Mar 10 '25	Sale	137.81	1,140	157,103	7,012	Mar 11 06:17 PM
Iannone Robert	Officer	Mar 10 '25	Proposed Sale	145.00	1,767	256,215		Mar 10 06:01 PM
Carr Patricia	Officer	Mar 10 '25	Proposed Sale	137.81	1,140	157,103		Mar 10 05:36 PM
Iannone Robert	EVP, Global Head of R&D & CMO	Mar 07 '25	Sale	138.60	7,080	981,298	82,024	Mar 07 06:49 PM
ROBERT IANNONE	Officer	Mar 07 '25	Proposed Sale	138.73	5,466	758,305		Mar 07 05:14 PM
Iannone Robert	Officer	Mar 07 '25	Proposed Sale	142.26	4,017	571,476		Mar 07 05:04 PM
Henderson Mary Elizabeth	Officer	Mar 07 '25	Proposed Sale	139.00	1,295	180,005		Mar 07 03:15 PM
Carr Patricia	SVP, Chief Accounting Officer	Feb 27 '25	Option Exercise	113.77	4,813	547,562	12,737	Mar 03 07:21 PM
Carr Patricia	SVP, Chief Accounting Officer	Feb 27 '25	Sale	144.42	4,813	695,075	8,237	Mar 03 07:21 PM
Carr Patricia	SVP, Chief Accounting Officer	Feb 28 '25	Sale	143.29	773	110,767	9,485	Mar 03 07:21 PM
Patil Neena M	EVP & Chief Legal Officer	Feb 27 '25	Sale	144.87	3,800	550,506	33,318	Mar 03 07:18 PM
COZADD BRUCE C	Chairman & CEO	Mar 03 '25	Sale	144.25	6,500	937,625	464,058	Mar 03 07:13 PM
COZADD BRUCE C	Officer	Mar 03 '25	Proposed Sale	144.25	6,500	937,625		Mar 03 04:44 PM
Carr Patricia	Officer	Feb 28 '25	Proposed Sale	143.30	773	110,767		Feb 28 05:43 PM
Carr Patricia	Officer	Feb 27 '25	Proposed Sale	139.00	1,641	228,099		Feb 27 08:05 PM
Carr Patricia	Officer	Feb 27 '25	Proposed Sale	144.42	4,813	695,075		Feb 27 05:04 PM
Patil Neena M	Officer	Feb 27 '25	Proposed Sale	144.87	3,800	550,518		Feb 27 04:56 PM
COZADD BRUCE C	Chairman & CEO	Feb 03 '25	Sale	122.31	1,500	183,465	439,744	Feb 05 05:41 PM
COZADD BRUCE C	Officer	Feb 03 '25	Proposed Sale	122.31	1,500	183,465		Feb 03 05:04 PM
COZADD BRUCE C	Chairman & CEO	Jan 02 '25	Sale	123.43	1,500	185,145	425,525	Jan 06 04:22 PM
COZADD BRUCE C	Officer	Jan 02 '25	Proposed Sale	123.43	1,500	185,145		Jan 02 05:00 PM
COZADD BRUCE C	Chairman & CEO	Dec 02 '24	Sale	121.17	2,000	242,340	427,025	Dec 04 05:24 PM
Carr Patricia	SVP, Chief Accounting Officer	Dec 02 '24	Sale	122.49	53	6,492	6,596	Dec 04 05:20 PM
COZADD BRUCE C	Officer	Dec 02 '24	Proposed Sale	121.17	2,000	242,340		Dec 02 06:05 PM
Carr Patricia	Officer	Dec 02 '24	Proposed Sale	122.49	53	6,492		Dec 02 04:20 PM
Patil Neena M	EVP & Chief Legal Officer	Nov 08 '24	Sale	123.41	3,700	456,617	33,048	Nov 13 05:44 PM
Patil Neena M	Officer	Nov 08 '24	Proposed Sale	123.41	3,700	456,632		Nov 08 05:55 PM
COZADD BRUCE C	Chairman & CEO	Nov 01 '24	Sale	110.84	1,000	110,840	428,976	Nov 05 05:00 PM
COZADD BRUCE C	Officer	Nov 01 '24	Proposed Sale	110.84	1,000	110,840		Nov 01 03:19 PM

JAZZ

Jazz Pharmaceuticals plc

Upgrade your FINVIZ experience